Will Kinase Inhibitors Make it as Glioblastoma Drugs?
| Autor: | Nikolaus Schultz, Ingo K. Mellinghoff, Paul S. Mischel, Timothy F. Cloughesy |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Antineoplastic Agents
Article Receptor tyrosine kinase Proto-Oncogene Proteins p21(ras) Phosphatidylinositol 3-Kinases Proto-Oncogene Proteins medicine Humans Epidermal growth factor receptor Protein Kinase Inhibitors PI3K/AKT/mTOR pathway Phosphoinositide-3 Kinase Inhibitors Platelet-Derived Growth Factor Sirolimus Clinical Trials as Topic biology Kinase TOR Serine-Threonine Kinases PTEN Phosphohydrolase Cancer medicine.disease ErbB Receptors Drug Resistance Neoplasm Mutation ras Proteins biology.protein Cancer research Signal transduction Glioblastoma Signal Transduction medicine.drug |
| Zdroj: | Therapeutic Kinase Inhibitors ISBN: 9783642282959 |
| Popis: | Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Attempts to target the Ras—Phosphatidylinositol 3-kinase (PI3K)—mammalian Target of Rapamycin (mTOR) axis in GBM with first generation receptor tyrosine kinase (RTK) inhibitors and rapalogs have been disappointing. However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors. This chapter reviews common genetic alterations in growth factor signaling pathways in GBM, their validation as therapeutic targets in this disease, and strategies for future clinical development of kinase inhibitors for high grade glioma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|